What is HC Wainwright’s Estimate for Climb Bio Q3 Earnings?

Climb Bio, Inc. (NASDAQ:CLYM) – HC Wainwright lifted their Q3 2026 EPS estimates for Climb Bio in a research note issued to investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.20) for the quarter, up from their prior forecast of ($0.23). HC Wainwright currently has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Climb Bio’s Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.98) EPS.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03.

Several other research firms have also commented on CLYM. Guggenheim began coverage on Climb Bio in a research report on Monday, June 8th. They set a “buy” rating and a $35.00 price target for the company. BTIG Research increased their target price on Climb Bio from $19.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Chardan Capital initiated coverage on Climb Bio in a research note on Tuesday, May 5th. They set a “buy” rating and a $22.00 target price on the stock. Robert W. Baird set a $21.00 target price on Climb Bio in a report on Wednesday, May 6th. Finally, Royal Bank Of Canada assumed coverage on Climb Bio in a research report on Monday, August 3rd. They issued an “outperform” rating and a $23.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $23.08.

Climb Bio Stock Up 8.8%

Shares of NASDAQ CLYM opened at $17.84 on Wednesday. The business’s 50 day moving average is $13.59 and its two-hundred day moving average is $10.29. Climb Bio has a 52-week low of $1.54 and a 52-week high of $18.33. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -21.49 and a beta of 0.08.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in Climb Bio in the 2nd quarter valued at about $45,000. California State Teachers Retirement System acquired a new position in shares of Climb Bio during the second quarter worth about $82,000. Virtu Financial LLC purchased a new stake in shares of Climb Bio during the fourth quarter worth approximately $43,000. Blair William & Co. IL purchased a new stake in shares of Climb Bio during the fourth quarter worth approximately $44,000. Finally, Balyasny Asset Management L.P. acquired a new stake in Climb Bio in the fourth quarter valued at approximately $57,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.